Company intelligence / Profile preview
Theragenics
- Ownership
- Private
- Development stage
- Commercial
Overview
Theragen Bio is a global genome service provider with a strong focus on precision medicine. The company has developed advanced genomic analysis capabilities and is leveraging these to develop personalized anti-cancer drugs. Its lead asset "Vactosertib" is undergoing clinical trials for various cancers including colon and lung cancer. The company also aims to develop targeted therapies against specific oncogenic drivers such as MAPK3 and is exploring the development of therapeutic vaccines for cancer
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeVaccine
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Theragenics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Theragenics.